Immunic Inc (NASDAQ: IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and a corporate update. Dr. Vitt says that the performance of the business during Q2 "couldn't have been better", highlighting what he calls "scientifically a very good quarter and uneventful on the more general financial side."
He goes on to give more detail about the progress achieved with Immunic's prospective multiple sclerosis (MS) and celiac disease treatments during the quarter, noting the preclinical data for its most advanced molecule IMU-838 that was published in the Journal of Medicinal Chemistry and positive results From Phase 1b Clinical Trial of IMU-856 in celiac disease. Looking to the future, Dr. Vitt expects more trial data to be released in the fall of this year, and reiterates that the company is fully funded into Q4 of 2024.
Contact Details
Proactive United States
+1 347-449-0879
